DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
TXG logo

10x Genomics, Inc. Stock Price

NasdaqGS:TXG Community·US$8.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 40 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

TXG Share Price Performance

US$67.29
54.70 (434.47%)
​
US$49.54
Fair Value
US$67.29
54.70 (434.47%)
35.8% overvalued intrinsic discount
US$49.54
Fair Value
Price US$67.29
AnalystConsensusTarget US$49.54
AnalystHighTarget US$68.25
AnalystLowTarget US$17.00
Thu, 20 Aug 26
Fair ValueUS$49.54
Share Pricen/a

TXG Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$49.54 35.8% overvalued intrinsic discount

Advanced Genomics Tools Will Shape Future Precision Medicine

0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$68.25 1.4% undervalued intrinsic discount

Advanced Genomics Trends Will Unlock Precision Medicine

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$17 295.8% overvalued intrinsic discount

US Funding Cuts And Global Pressures Will Hamper Progress

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
TXG logo
10x Genomics
35.8% overvalued intrinsic discount

Advanced Genomics Tools Will Shape Future Precision Medicine

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 20 Aug
Read Narrative
TXG logo
10x Genomics
1.4% undervalued intrinsic discount

Advanced Genomics Trends Will Unlock Precision Medicine

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 3 Sep
Read Narrative
TXG logo
10x Genomics
295.8% overvalued intrinsic discount

US Funding Cuts And Global Pressures Will Hamper Progress

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 12 May
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
TXG logo

TXG: Cancer Collaborations And AI Drug Discovery Uses Will Shape Balanced Outlook

Fair Value: US$68.25 1.4% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
TXG logo

TXG: Elevated AI Demand Expectations Will Pressure Overextended Near Term Setup

Fair Value: US$49.54 35.8% overvalued intrinsic discount
24 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
TXG logo

TXG: 2026 Academic Demand Weakness Will Challenge Elevated Expectations

Fair Value: US$17 295.8% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
1 Reward
View Full Analysis

10x Genomics, Inc. Key Details

US$616.9m

Revenue

US$184.4m

Cost of Revenue

US$432.5m

Gross Profit

US$507.7m

Other Expenses

-US$75.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.58
70.11%
-12.18%
0%
View Full Analysis

About TXG

Founded
2012
Employees
1178
CEO
Serge Saxonov
WebsiteView website
www.10xgenomics.com

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3’ gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Recent TXG News & Updates

User avatar
Narrative Update • Sep 03

TXG: Cancer Collaborations And AI Drug Discovery Uses Will Shape Balanced Outlook

The analyst price target for 10x Genomics has moved from $50 to about $68, with analysts pointing to updated models that reflect the Atera launch, spatial and consumables demand, and the company's positioning around AI driven drug development as key supports for the higher valuation assumptions. Analyst Commentary Recent Street research on 10x Genomics points to a cluster of price target increases tied to Atera, spatial biology adoption, and updated revenue models.

Recent updates

No updates

10x Genomics, Inc. Competitors

MRNA logo

Moderna

Symbol: NasdaqGS:MRNA
Market cap: US$56.0b
NTRA logo

Natera

Symbol: NasdaqGS:NTRA
Market cap: US$46.7b
RVMD logo

Revolution Medicines

Symbol: NasdaqGS:RVMD
Market cap: US$44.4b
TEVA logo

Teva Pharmaceutical Industries

Symbol: NYSE:TEVA
Market cap: US$42.8b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide